Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Shepherd

Showing results (71-80 of 105) with videos related to

Pageof 11
Sort By:
Human Genetics|October 2, 2010
Genetic variants in the KIF6 region and coronary event reduction from statin therapyYonghong Li, Marc S Sabatine, Carmen H Tong, et al.
Atherosclerosis|December 24, 2011
KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderlyHironobu Akao, Eliana Polisecki, Kouji Kajinami, et al.
Atherosclerosis|December 23, 2011
Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderlyHironobu Akao, Eliana Polisecki, Kouji Kajinami, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Diabetes Care|November 13, 2008
Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly populationPaul Welsh, Heather M Murray, Brendan M Buckley, et al.
Journal of Lipid Research|September 16, 2009
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderlyEliana Polisecki, Inga Peter, Jason S Simon, et al.
The American Journal of Cardiology|November 27, 2007
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinPaul M Ridker, Francisco A H Fonseca, Jacques Genest, et al.
Lancet (London, England)|March 31, 2009
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialPaul M Ridker, Eleanor Danielson, Francisco Ah Fonseca, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, et al.
Pageof 11

Showing results (71-80 of 105) with videos related to

Sort By:
Pageof 11
Human Genetics|October 2, 2010
Genetic variants in the KIF6 region and coronary event reduction from statin therapyYonghong Li, Marc S Sabatine, Carmen H Tong, et al.
Atherosclerosis|December 24, 2011
KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderlyHironobu Akao, Eliana Polisecki, Kouji Kajinami, et al.
Atherosclerosis|December 23, 2011
Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderlyHironobu Akao, Eliana Polisecki, Kouji Kajinami, et al.
Plos One|December 23, 2014
Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Journal of the American College of Cardiology|December 28, 2010
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkersBenoit J Arsenault, Philip Barter, David A DeMicco, et al.
Diabetes Care|November 13, 2008
Leptin predicts diabetes but not cardiovascular disease: results from a large prospective study in an elderly populationPaul Welsh, Heather M Murray, Brendan M Buckley, et al.
Journal of Lipid Research|September 16, 2009
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderlyEliana Polisecki, Inga Peter, Jason S Simon, et al.
The American Journal of Cardiology|November 27, 2007
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinPaul M Ridker, Francisco A H Fonseca, Jacques Genest, et al.
Lancet (London, England)|March 31, 2009
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialPaul M Ridker, Eleanor Danielson, Francisco Ah Fonseca, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER)Paul M Ridker, Jean G MacFadyen, Francisco A H Fonseca, et al.
Pageof 11